Fundraising Fox
/Companies
Sign in

Sapience Therapeutics

Scarsdale, US · Founded 2015 · Delaware corporation · 23 employees on LinkedIn · 5 known investors

Find your way into Sapience Therapeutics

Each arrow is one introduction. Sign up to fill in the first one.

167 people can intro you to Abi

Ask Nurit Benjamini to introduce you to Abi Vainstein-Haras

You →Nurit · together at Biolinerx →Abi

Sign up to find every way you can get introduced to Sapience Therapeutics

  • Your email: who you already know at Sapience Therapeutics, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Sapience Therapeutics team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Sapience Therapeutics is a clinical-stage biotechnology company developing peptide-based cancer therapies that target traditionally undruggable oncogenic proteins and protein-protein interactions. Its pipeline includes SPEAR peptides that act inside cancer cells and SPARC peptides that act on the outside, with lead candidates lucicebtide (ST101) and ST316 in Phase 2 oncology trials.

BiotechHealthtech

Founders & leadership

Sapience Therapeutics was founded in 2015 by Barry Kappel, Ph.D..

BK
Barry Kappel, Ph.D.Founder
AVAbi Vainstein-Haras
Abi Vainstein-HarasChief Medical OfficerAbi Vainstein-Haras is an oncology clinical development leader with over 15 years of experience across early-stage and late-phase programs, including work on motixafortide's development and approval. She has extensive expertise in clinical strategy, regulatory interactions with the FDA and EMA, study design, and cross-functional team leadership across multiple oncology indications.
MFMarisa Frackman
Marisa FrackmanChief Financial Officer
SISeth I. Rubin
Seth I. RubinGeneral Counsel

Board

IB
Isaac BlechBoard director
RR
Robert Ruffolo, Ph.D.Board director
DS
David Scheinberg, Ph.D.Board director

Investors · 5

Eshelman Ventures, LLClisted by Eshelman Ventures, LLCWilmingtonvia Fred Eshelman · inferred

How we know: prnewswire.com · Not right? Tell us

Also in the syndicate · 3

Bristol Myers SquibbKingdon CapitalNexPointlead

Funding

SEC filings, press & company announcements

$49.3M disclosed across 3 of 5 rounds · 2015–2022

▶$8MraisedJul 2020 · 83 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Christian SchadeDirector
  • Barry KappelExecutive Officer, Director
  • David ScheinbergDirector
  • Howard PienDirector
  • Robert RuffoloDirector
Offering amount
$30M
Amount sold
$8M
Minimum investment
$50K
Sales commissions
$701.1K
Placement agents
Maxim Group LLC
First sale
Jun 2020
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$22.5MofferedApr 2016 · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Robert Ruffolo, Ph.D.Director
  • Barry Kappel, Ph.D.Executive Officer, Director
  • David Scheinberg, Ph.D.Director
  • Howard PienDirector
  • Isaac BlechDirector
Offering amount
$22.5M
Minimum investment
$50K
Sales commissions
$800K
Placement agents
Maxim Group LLC
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$300KraisedJan 2016 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Robert Ruffolo, Ph.D.Director
  • David Scheinberg, Ph.D.Director
  • Isaac BlechDirector
  • Barry Kappel, Ph.D.Executive Officer, Director
Offering amount
$1M
Amount sold
$300K
First sale
Dec 2015
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 2

SoluSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies working in the same space as Sapience Therapeutics.

In the news

Sapience Therapeutics Announces $41 Million Series B Financing to Advance Pipeline of Peptide Therapeutics Targeting Protein-Protein Interactionsprnewswire.com · May 2022Sapience Therapeutics Completes $14 million Preferred Stock Financing - Sapience Therapeuticssapiencetherapeutics.com · Nov 2020

Frequently asked questions

What does Sapience Therapeutics do?
Sapience Therapeutics is a clinical-stage biotechnology company developing peptide-based cancer therapies that target traditionally undruggable oncogenic proteins and protein-protein interactions. Its pipeline includes SPEAR peptides that act inside cancer cells and SPARC peptides that act on the outside, with lead candidates lucicebtide (ST101) and ST316 in Phase 2 oncology trials.
Who founded Sapience Therapeutics?
Sapience Therapeutics was founded by Barry Kappel, Ph.D. in 2015.
Who are Sapience Therapeutics's investors?
Sapience Therapeutics's investors include Connectivity Ventures, Eshelman Ventures, LLC.
How much funding has Sapience Therapeutics raised?
Sapience Therapeutics has disclosed $49.3M raised across 3 of its 5 known rounds.
Where is Sapience Therapeutics headquartered?
Sapience Therapeutics is headquartered in Scarsdale, US.